Acute Myeloid Leukemia Clinical Trial
Official title:
Phase I/II Trial of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Verified date | October 2023 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open label Phase I-II study to determine the safe doses of bortezomib, sitagliptin, and PTCy (Phase I) with expansion into a phase II trial to determine efficacy in improving survival.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients with any of the following hematologic malignancies: - Acute myeloid leukemia (AML) in first remission (CR1) if they have with intermediate or high-risk cytogenetic and/or molecular features, or patients in second or subsequent complete remission (CR2, CR3, etc.). Complete remission is defined as presence of <5% blasts in the bone marrow Version 09/30/2022 25 with no morphological evidence of leukemia. Patients in CR with incomplete count recovery may be included. - Acute lymphoblastic leukemia (ALL) with any of the following in CR1 or subsequent complete remission (CR2, CR3, etc.). Complete remission is defined as presence of <5% blasts in the bone marrow with no morphological evidence of leukemia. Patients in CR with incomplete count recovery may be included. - Myelodysplastic disorder (MDS) with a revised International Prognostic System Score (IPSS-R)104 of greater than 3 at diagnosis. Patients must have <10% blasts in the bone marrow documented within 30 days of transplant.* - Therapy-related myelodysplastic disorder (t-MDS). Patients must have <10% blasts in the bone marrow documented within 30 days of transplant.* - Chronic myelomonocytic leukemia (CMML) type 1 or 2. Patients must have <10% blasts in the bone marrow documented within 30 days of transplant.* *Patients with MDS, t-MDS, and CMML will be included only in the phase I portion of the study. 2. Patient age = 18 years 3. Karnofsky Performance status = 70% 4. Patients must also be suitable to receive a reduced-intensity (RIC) conditioning regimen at the discretion of the treating physician. While there are not universally accepted or validated cut-off criteria of age, performance status, or hematopoietic cell transplantation-comorbidity index (HCT-CI) for suitability for RIC, RIC transplants should be considered for patients 60 years and older, and for patients <60 years who are "less fit", e.g., KPS <90% and/or HCT-CI = 3 due to lower non-relapse mortality associated with RIC. 5. Patients receiving allogeneic peripheral blood stem cell (PBSC) grafts from HLA-matched (5/6 and 6/6 matches) siblings or matched unrelated donors (7/8 or 8/8 matches at HLA-A, B, C, DRB1 by high resolution typing) are included. All grafts will be unmanipulated (i.e., no T cell depleted or CD34 selected grafts). In addition, donors should meet institutional criteria for donation of PBSC, as well as the screening and eligibility criteria of the National Marrow Donor Program (NMDP) for unrelated donors, and the requirements of the United States Food and Drug Administration for Human Cell, Tissue, or Cellular or Tissue-based Products (HCT/P) (21 CFR Part 1271). 6. Required baseline laboratory values within 16 days prior to admission: - Estimated creatinine clearance >60 ml/min/1.72 m2 - Serum total bilirubin = 2 x upper limit of normal value (except for Gilbert's disease) - AST and ALT = 3 x upper limit of normal value - Alkaline phosphatase (ALP) = 250 IU/l 7. Required baseline values within 60 days prior to admission: - Left ventricular ejection fraction (LVEF) >40% Version 09/30/2022 26 - Adjusted carbon monoxide diffusing capacity (DLCO) >50% 8. No evidence of HIV infection (Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies.) 9. Non-pregnant and non-nursing 10. Signed written informed consent 11. Patients must otherwise fulfill institutional criteria for eligibility to undergo reduced-intensity allogeneic stem cell transplantation. Exclusion Criteria: 1. Pregnant or nursing females or women of reproductive capability who are unwilling to completely abstain from heterosexual sex or practice 2 effective methods of contraception from start of conditioning through a minimum of 90 days after the last dose of study drug. 2. Male subjects who refuse to practice effective barrier contraception from the start of conditioning through a minimum of 90 days after the last dose of study drug, or completely abstain from heterosexual intercourse. 3. Inability to provide informed consent. 4. Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. 5. Patients with active central nervous system leukemia 6. Prior allogeneic HSCT or an autologous hematopoietic stem cell transplant in past 12 months 7. Patients with diabetes mellitus requiring insulin secretagogues and/or insulin at time of enrollment. 8. Patients with a history of pancreatitis 9. Patients with symptomatic cholelithiasis 10. Known hypersensitivity to any of the components of the investigational treatment regimen. 11. Serious medical or psychiatric illness likely to interfere with participation in this clinical study. 12. Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma, an in-situ malignancy, or low-risk prostate cancer after curative therapy. 13. Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial. 14. Prisoners |
Country | Name | City | State |
---|---|---|---|
United States | Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose | in the first 30 days post-transplant | ||
Primary | proportion of patients developing grades 3-4 non-hematological toxicity defining DLT assessed by CTCAE version 5.0 | in the first 30 days post-transplant | ||
Primary | Proportion of patients alive and free of grade II-IV acute GVHD (graft-versus-host disease) | Baseline to day +100 | ||
Primary | Cumulative incidence of grade II-IV acute GVHD | through study completion (i.e. up to 5 years) | ||
Secondary | Frequency of Non-Hematological toxicity as assessed by CTCAE version 5.0 | baseline to day +30 | ||
Secondary | Cumulative incidences of all grades of acute GvHD | baseline to day +100 | ||
Secondary | Chronic graft-versus-host disease | through study completion (i.e. up to 5 years) | ||
Secondary | Time to engraftment of neutrophils | the time from day 0 to the date of the first of three consecutive days after transplantation during which the absolute neutrophils count (NEUTROPHILS + BANDS) is at least 0.5 x109/l. | ||
Secondary | Time to engraftment of platelets | the time to engraftment of platelets is defined as the time from day 0 to the first of seven consecutive days after transplantation during which the platelet count is at least 20 x109/l without transfusion support. | ||
Secondary | Cumulative Incidence engraftment of neutrophils and platelets | day 0 to the first of seven consecutive days after transplantation during which the platelet count is = 20 x109/l and ANC is = 0.5 x109/l without transfusion. | ||
Secondary | cumulative incidence of non-relapse mortality | through study completion (i.e. up to 5 years) | ||
Secondary | cumulative incidence of relapse | through study completion (i.e. up to 5 years) | ||
Secondary | Graft-versus-host free, and relapse-free survival (GRFS) | Baseline to day+365 | ||
Secondary | chronic GvHD immunosuppression-free survival | Baseline through day+365 | ||
Secondary | Grade III-IV acute GvHD-free survival | baseline through day +180 | ||
Secondary | Progression-free Survival in all enrolled subjects | Baseline through day+365 | ||
Secondary | Overall Survival in all enrolled subjects | Baseline through day+365 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |